Radio Pharmaceuticals Market 2019 | Future Growth By Leading Key Players Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company

Radiopharmaceuticals are medicinal formulations that contain radioisotopes, which are used in major clinical areas for diagnosis and/or therapy. Radiopharmaceuticals have several applications in diagnostic as well as therapeutic areas in nuclear medicine. There are around 50 U.S. Food & Drug Administration (FDA) approved radiopharmaceuticals present in the market for diagnostic and therapeutic applications. Technetium -99m has vast number of applications in diagnostic imaging using radiopharmaceuticals. Areas where radiopharmaceuticals have applications include oncology, neurology, hematology, cardiology, thyroid applications, and others. Moreover, certain radiopharmaceuticals have diagnostic as well as therapeutic applications such as certain iodine isotopes.

Radiopharmaceuticals such as Vizamyl (GE Healthcare), Amyvid (Eily, Lilly, and Company), and Neuraceq (Life Molecular Imaging) are indicated to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment, who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. Hematology applications include determination of total blood volume, plasma volume, cardiac output, glomerular filtration, and other tests. Products used in hematology include Jeanatope, Megatope, and Glofil-125 manufactured by IsoTex Diagnostics. Cardiology applications mainly include myocardial perfusion imaging for distinguishing normal from abnormal myocardium in patients with suspected myocardial infarction and other applications.

Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/70

The global radiopharmaceuticals in nuclear medicine market size was valued at US$ 4,986.4 million in 2017 and is expected to witness a robust CAGR of 8.9% over the forecast period (2018–2026).

Technological advancements in imaging have brought many changes such as the introduction of hybrid technology — positron emission tomography/computed tomography (PET/CT) and single-photon emission computed tomography/computed tomography (SPECT/CT). Combination of the anatomic details provided, for instance, by CT, with the important and much needed functional, physiologic or metabolic information provided by molecular imaging has been facilitated with the use of hybrid imaging.

More accurate diagnosis is possible with the help of hybrid imaging with increased specificity, attenuation correction, and localization. Moreover, usage of PET/CT has been established in clinical practice and has added significant value in the areas of neurology, cardiology, and oncology. Moreover, SPECT/CT has also been established and has been used in areas such as cardiology, liver/spleen imaging, thyroid imaging, cancer diagnosis, and others.

Hybrid imaging (PET/CT) along with radiopharmaceuticals such as 18F-fluorodeoxyglucose (18F-FDG), the most frequently used molecule in the PET diagnosis, 18F-fluorothymidine (18F-FLT), 18F-fluorocholine (18F-FCH), 18F-fluoro-ethyltyrosine (18F-FET), 18F-fluorodihydroxyphenylalanine (18F-FDOPA), 11C-methionine (11C-MET) or 18F-fluoromisonidazole (18F-FMISO), 68Ga-DOTA derivatives, 68Ga-PSMA, 18F-florbetaben or 18F-flutemetamol for brain amyloid beta imaging has been widely used (according to European Journal of Radiology, 2017). These factors drive growth of the market and further developments in PET cameras and other technologies is expected to boost growth of the market over the forecast period.

Receive Sample on Radiopharmaceuticals Research: https://www.coherentmarketinsights.com/insight/request-sample/70

However, factors such as high costs of development of radiopharmaceuticals relative to return on investment, supply shortage of radiopharmaceuticals, and short half-life of radiopharmaceuticals is expected to restrain growth of the radiopharmaceuticals in nuclear medicine market over the forecast period.

Detailed Segmentation:

Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
Tc-99m
In-111
Tl-201
Ga-67
I-123/I-125/I-131
Other SPECT Isotopes
PET Radiopharmaceuticals
F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben
F-18-Fluoro-Deoxy-Glucose (18F-FDG)
Fluorine-18 Fluciclovine
Other F-18 Isotopes
Ru-82
Other PET Isotopes
Therapeutic Nuclear Medicine
Ra-223
I-131
Re-186/Sm-153/Sr-90
Lu-177
Ir-192
Pd-103
Cs-131
Others
Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
Oncology
Cardiology
Neurology
Endocrinology
Others
Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
Hospitals
Specialty Clinics
Diagnostic Centers

Some major players operating in the global radiopharmaceuticals in nuclear medicine market include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., and Eli Lilly and Company.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/70

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.